[FUL] H.B. Fuller: Q3 2026 Earnings Preview as the April Price Increase Meets Falling Volume

H.B. Fuller is the world's largest pureplay adhesives company, formulating and supplying adhesives and specialty chemical products to manufacturers of food and beverages, hygiene products, electronics, aerospace and defense products, construction materials, roofing systems, windows, doors, packaging, and tapes and labels, delivered mainly from its own plants and distribution centers with additional volume moving through distributors[1]. The company holds its investor call on 2026-09-24, covering the Fiscal 2026 third quarter, the three months ended August 29, 2026[2]. The most recent disclosed period is the fiscal second quarter, when net revenue was $950.3 million, up 5.8% year-on-year, with product pricing adding 3.0 percentage points and volume subtracting 0.4, adjusted gross margin reaching 34.2% after 200 basis points of year-on-year expansion, adjusted EBITDA of $181 million, up 9%, and adjusted diluted earnings per share of $1.41[3]. For the quarter now being reported, the company guided on June 25 to mid-single-digit revenue growth and adjusted EBITDA of $180 million to $190 million[4], and management said on the same day's call that pricing should reach high single-digit growth approaching double digits in the second half while volume declines mid-single digits[5]; outside the company, MarketBeat's compiled analyst averages for the quarter are earnings of $1.47 per share on revenue of $948.2 million[6].

Three things in this report are worth watching. First is the net of price and volume: the minimum 10% increase across all product lines globally took effect on April 1, 2026, so the fiscal third quarter is the first full period in which it applies throughout, and the first for which management has warned that volume will fall mid-single digits, which is why the pricing percentage and the volume percentage in the revenue variance analysis have to be read together rather than separately[7][8]. Second is underlying demand in Engineering Adhesives once the exit from the lower-margin solar business stops obscuring it: segment net revenue was $283.2 million in the second quarter while organic revenue fell 1.0%, management put organic growth excluding solar at about 5%, and it has said solar revenue troughs in the third quarter, so the coming report is the first chance to read the segment without that obstruction[9][5]. Third is cash: first-half operating cash flow was $117.2 million against full-year guidance of $300 million to $325 million, and net debt stood at $1,958 million, or 3.1 times adjusted EBITDA, so whether leverage is still falling on the company's own cash before the Advanced Medical Solutions debt arrives gets its first answer in this quarter[10][11].

Company Background and Business Structure

H.B. Fuller was founded in 1887, is headquartered in St. Paul, Minnesota, and describes itself as a global formulator, manufacturer and marketer of adhesives and other specialty chemical products. Fiscal 2025 net revenue, for the year ended November 29, 2025, was $3,473.6 million, and at that date the company had approximately 7,100 employees in 44 countries, including about 2,500 in the United States, serving a customer base diverse enough that no single customer accounted for more than 10 percent of consolidated net revenue[1]. International operations are the main body of the business rather than an extension of it: approximately 56 percent of fiscal 2025 net revenue, or $2.0 billion, was generated outside the United States[12].

The company reports three segments. Hygiene, Health and Consumable Adhesives serves the assembly, packaging, converting, nonwoven, hygiene, health and beauty, flexible packaging, graphic arts and envelope markets and produced $1,551.8 million of fiscal 2025 net revenue, about 45 percent of the total; Engineering Adhesives supplies high-performance adhesives to the transportation, electronics, clean energy, aerospace and defense, textile, appliance and heavy machinery markets and produced $1,061.8 million, about 31 percent; Building Adhesive Solutions provides specialty adhesives, sealants, tapes and application devices for commercial roofing systems, heavy infrastructure projects, telecom and 5G utilities, industrial LNG plants, building envelope applications, HVAC insulation, performance woodworking and insulating glass, and produced $860.0 million, about 25 percent[13].

By region, fiscal 2025 net revenue was $1,782.3 million in the Americas, $1,046.6 million in EIMEA, which covers Europe, India, the Middle East and Africa, and $644.7 million in Asia Pacific[13]. The chief executive officer acts as chief operating decision maker and reviews each segment on revenue and adjusted EBITDA to allocate resources, which makes segment adjusted EBITDA the most direct measure of where the company puts its own money[14]. One structural change is pending: the acquisition of the United Kingdom's Advanced Medical Solutions would add a medical adhesives business and would have taken pro forma 2025 revenue to $3.8 billion[15].

Financial History and Current Position

On revenue, the last several years trace a flat to slightly declining line. Net revenue rose from $3,278.0 million in fiscal 2021 to $3,749.2 million in fiscal 2022, fell back to $3,510.9 million in fiscal 2023, was $3,568.7 million in fiscal 2024 and $3,473.6 million in fiscal 2025, a 2.7 percent decline in the latest year[16]. That decline did not come from shrinking operations: organic revenue was flat, consisting of a 0.8 percent contribution from product pricing offset by a 0.8 percent decline in sales volume, while acquisitions and divestitures subtracted 2.1 percent and currency 0.6 percent[17].

While revenue stayed flat, margin climbed. Fiscal 2025 cost of sales was $2,392.9 million, or 68.9 percent of net revenue, 130 basis points lower year-on-year, with raw material cost down 100 basis points as a share of revenue; gross profit rose to $1,080.7 million at a 31.1 percent margin, 130 basis points higher, and selling, general and administrative expense was $725.6 million, or 20.9 percent of revenue[18]. Net income attributable to H.B. Fuller for the same year was $152.0 million, adjusted EBITDA was $620.7 million at a 17.9 percent margin, and adjusted diluted earnings per share were $4.24[16].

The first two quarters of fiscal 2026 look nothing alike. First-quarter net revenue was $770.8 million and organic revenue fell 6.6 percent year-on-year, made up of a 7.2 percent decline in sales volume against only 0.6 percent of pricing, plus 3.6 percent from currency and 0.7 percent from acquisitions[19]; even so, adjusted gross margin rose 170 basis points to 31.3 percent, adjusted EBITDA was $118.7 million, up 4 percent, and adjusted earnings per share were $0.57, which the company attributed to restructuring savings from Quantum Leap, the impact of acquisitions, and targeted price and raw material cost actions[20]. Second-quarter net revenue recovered to $950.3 million, up 5.8 percent, with organic growth of 2.6 percent built from 3.0 percent pricing, minus 0.4 percent volume, 3.1 percent currency and 0.1 percent acquisitions[8], and raw material cost as a percentage of net revenue fell 230 basis points year-on-year, which is the main source of the expansion in adjusted gross margin to 34.2 percent[21].

At the segment level, the three businesses did not move together in the second quarter. Hygiene, Health and Consumable Adhesives revenue was $421.9 million, up 6.1 percent, segment adjusted EBITDA rose 21.7 percent from $62.1 million to $75.6 million, and the margin improved 230 basis points to 17.9 percent, with almost all of the gain coming from pricing[22]. Engineering Adhesives revenue was $283.2 million, up 2.5 percent, but organic revenue fell 1.0 percent, segment adjusted EBITDA was essentially flat at $63.5 million and the margin slipped 50 basis points to 22.4 percent, still the highest of the three segments[9]. Building Adhesive Solutions revenue was $245.2 million, up 9.4 percent, with organic growth of 6.2 percent that the 10-Q attributes to an increase in both sales volume and product pricing, while segment adjusted EBITDA rose from $37.5 million to $41.4 million and the margin improved 20 basis points to 16.9 percent[23].

The balance sheet and the cash flow statement carry the weight of the strategy. Net debt at the end of the second quarter was $1,958 million, $58 million lower year-on-year, and net debt to adjusted EBITDA was 3.1 times against 3.4 times a year earlier; operating cash flow of $121 million was a second-quarter record, net working capital improved 260 basis points sequentially to 16.4 percent of annualized net revenue, and the company said cash delivery for 2026 is weighted to the second half[11]. Cumulative first-half operating cash flow was nevertheless only $117.2 million, against capital spending of $104.4 million, dividends of $26.0 million and buybacks of $48.8 million, with accounts receivable absorbing $53.9 million and inventory $51.3 million[10]. In July the company refinanced its bank debt, extending a $420 million term A loan and a revolving facility enlarged to $800 million to July 17, 2031 and cutting interest rate margins by 25 basis points[24]. Management guides fiscal 2026 to mid-single-digit revenue growth, adjusted EBITDA of $650 million to $675 million, adjusted earnings per share of $4.60 to $4.90 and operating cash flow of $300 million to $325 million, and states that none of it includes the pending Advanced Medical Solutions acquisition[4].

Operating Model

Net revenue equals realized price times volume, plus acquisitions and currency translation, and the company decomposes its own revenue change into exactly those four parts every quarter[8]. Volume comes from customers' own production schedules: hygiene and packaging converters for Hygiene, Health and Consumable Adhesives, electronics, aerospace and industrial assemblers for Engineering Adhesives, and the contractors who actually put roofing, infrastructure and glazing work in place for Building Adhesive Solutions[13]. Price is set by list increases announced globally and then realized over one to two quarters as contracts reprice, which is how the minimum 10 percent increase effective April 1, 2026 passes through; because adhesive is a small part of a customer's bill of materials but decides whether the product works, price moves faster than volume responds, and the volume that walks away is the cost of the increase[7].

Gross profit equals net revenue less raw material cost and other manufacturing cost. Raw materials are mostly resins, polymers, synthetic rubbers, vinyl acetate monomer and plasticizers that trace back to crude oil and natural gas, and the 10-K states plainly that the purchase of raw materials is the company's largest expenditure, bought on the open market or under contracts that limit the frequency but not the magnitude of supplier increases[16]. That exposure is quantified: based on 2025 results, a hypothetical one percent change in raw material costs would have changed net income by approximately $12.6 million, or $0.23 per diluted share[25]. Adjusted EBITDA is that gross profit less adjusted selling, general and administrative expense, and both lines are being worked on by three restructuring efforts at once — the plans approved in fiscal 2023, expected to cost $85.0 million to $90.0 million, of which $84.4 million had been incurred as of May 30, 2026; the Quantum Leap global supply chain rebuild; and the global footprint optimization actions approved in the fourth quarter of fiscal 2025, expected to cost $11.2 million to $13.0 million and to be completed during fiscal 2028[26].

The cash chain has one more lag in it than the profit chain. Operating cash flow is adjusted profit plus depreciation and amortization less the increase in net working capital, which the company tracks as net working capital over annualized net revenue[11]. A price-led year raises the carrying value of receivables and inventory before it raises collections, so cash trails profit by about a quarter, which is exactly why the company describes fiscal 2026 cash delivery as second-half weighted[10]. Below that line, the Quantum Leap plant and supply chain rebuild lifts capital spending, the dividend and share repurchases are steady claims on cash, and what is left determines net debt — and net debt over trailing adjusted EBITDA is the ruler against which the coming acquisition financing will be measured[15].

Parts of this model are limited by the disclosure itself and should be read with that in mind. Segment-level price and volume are described but not quantified, so segment organic growth cannot be decomposed the way the consolidated line can; restructuring savings are named repeatedly as a cause of margin improvement but never sized per quarter; and raw material cost appears only as a year-on-year ratio change, never as a level[21]. In addition, the exited solar business was last quantified in the first quarter of fiscal 2026, the net working capital ratio is computed on annualized revenue from the quarter just reported and therefore carries seasonality, and none of the fiscal 2026 guidance includes the acquisition that has not yet closed[7].

Industry and Competitive Position

H.B. Fuller positions itself as the largest pureplay adhesives formulator in a market that contains both global competitors with broad product ranges and narrower regional or specialty companies, where competition turns on product performance, supply assurance, technical service, quality, price and customer service[16]. The real barrier in this industry comes from an asymmetry: adhesive is a small share of the customer's bill of materials but determines whether the customer's product holds together and passes qualification, so customers tolerate price increases when supply is tight, and requalifying an approved alternative is slow and expensive[25].

The 2026 petrochemical disruption turned that asymmetry into a live test. Conflict in the Middle East severely constrained raw material availability, the company received more than 40 force majeure letters from suppliers covering feedstocks, intermediates, logistics lanes and energy inputs, and management argued that its global sourcing infrastructure let it keep supplying customers when competitors could not, then used that position to announce a minimum 10 percent price increase across all product lines globally effective April 1, 2026[7]. Management also cautioned that the aftershocks will persist even after activity in the Strait of Hormuz normalizes, that raw material costs are not expected to return to pre-disruption levels, and that the industry cost structure has been permanently reset[5]. The pending Advanced Medical Solutions acquisition points in a different direction, moving the mix toward medical adhesives, a fragmented market whose barriers to entry include regulatory approvals, clinical validation and rigorous customer qualification[27].

Core Debates

Can the minimum 10% global price increase H.B. Fuller put into effect on April 1, 2026 keep widening the gross spread in the fiscal third quarter without costing more volume than the mid-single-digit decline management has guided to?

This question comes first because the spread between what the company charges and what it pays is the single largest lever on its earnings. The purchase of raw materials is the company's largest expenditure, and the 10-K puts the sensitivity at approximately $12.6 million of net income for every one percent change in raw material cost, so that gap decides the income statement more than any volume assumption does[25]. The second quarter showed the lever working: pricing added 3.0 percentage points to net revenue against 0.4 points of volume decline for organic growth of 2.6 percent, raw material cost as a percentage of net revenue fell 230 basis points, adjusted gross margin reached 34.2 percent, up 200 basis points, and adjusted EBITDA was $181 million[3].

The financial transmission is a clean within-quarter relationship: realized price lifts net revenue while raw material cost for the quarter is largely fixed by contract, so nearly all of the incremental price falls into gross profit, and the volume lost to that price removes the associated revenue, gross profit and fixed-cost absorption, leaving adjusted EBITDA to be set by the net of the two in the same quarter[21]. The quality of the second quarter is open to a second reading, however. Hygiene, Health and Consumable Adhesives organic revenue had fallen 10 percent year-on-year in the first quarter, and management attributed $15 million to $20 million of that first-quarter shortfall to Chinese New Year timing that pushed revenue into the second quarter, which means part of the second-quarter volume was moved rather than won, and pricing was only 0.6 percent before the April increase took effect[7]. The fiscal third quarter is the first period that sits entirely under the new price while management has already warned of a mid-single-digit volume decline, so the two readings meet head-on in this report.

Judging it requires reading the pricing and volume percentages in the third-quarter revenue variance analysis together, checking whether raw material cost as a percentage of net revenue still improves year-on-year once the prior-year comparison hardens, watching whether adjusted gross margin holds above 34 percent on lower volume, which is what would separate spread from absorption, and seeing whether the full-year adjusted EBITDA range of $650 million to $675 million is maintained, raised or narrowed toward its low end[4]. Three observable falsifiers follow: a price contribution below +6.0% in the third quarter would mean the announced increase is not being realized; volume worse than -7.0% would mean the increase is costing more quantity than management planned for; and adjusted gross margin below 32.2% would erase the year-on-year expansion this understanding rests on[8].

Management says the drag from exiting the lower-margin solar business troughs in the fiscal third quarter. When it does, will Engineering Adhesives organic revenue growth turn positive on electronics, aerospace and general industrial demand?

Engineering Adhesives is the segment H.B. Fuller has been reshaping toward higher-value markets and the most profitable of the three, with a second-quarter segment adjusted EBITDA margin of 22.4 percent that sits clearly above the other two[14]. The problem is that reported organic growth keeps coming in negative because the company is deliberately walking away from solar revenue, so investors cannot currently read underlying demand from the headline number — and management says that obstruction clears in the third quarter[5].

The current evidence points both ways. Second-quarter Engineering Adhesives net revenue was $283.2 million, up 2.5 percent, while organic revenue fell 1.0 percent, segment adjusted EBITDA of $63.5 million was almost unchanged from a year earlier, and the margin of 22.4 percent was 50 basis points lower, which the company attributed to the higher revenue base and to compensation tied to higher projected profit[9]; on the call, management said organic revenue excluding the exited lower-margin solar business grew about 5 percent year-on-year, driven by aerospace, electronics and general industries[5]. In the first quarter the company quantified solar revenue at about $12.5 million, down 40 percent, and said it was on track to trough by the third quarter[7]. In transmission terms, solar revenue leaving the base subtracts directly from segment net revenue until it annualizes; once that stops, segment revenue reflects electronics, aerospace and industrial order rates, and because this segment carries the group's highest margin, each dollar of revenue swing moves segment adjusted EBITDA by roughly a fifth as much within the same quarter.

The alternative reading is that Engineering Adhesives is not only a solar story: automotive demand was weak across the same quarters and management expects that weakness to persist through the second half, so the segment could stop shrinking without starting to grow. Separating the two requires watching whether the third-quarter 10-Q reports positive Engineering Adhesives organic revenue growth with no "excluding solar" qualifier attached, whether management still quantifies solar revenue and at what level relative to the roughly $12.5 million first-quarter figure, whether the segment adjusted EBITDA margin recovers to 22.4 percent or above once variable compensation normalizes, and which end markets management names as the source of growth, including whether automotive is still called out as weak[9]. The falsifiers are equally concrete: organic growth still negative after the disclosed solar trough would relocate the problem from the exited business to the continuing one; a segment margin below 21.9% would suggest the exit is not improving mix as claimed; and a deferred solar trough would push the test out by at least two quarters.

Was the 6.2% organic growth Building Adhesive Solutions delivered in the fiscal second quarter real project demand in glass, infrastructure and mechanical end markets, or first-quarter work that weather pushed one quarter later?

Building Adhesive Solutions is the only one of the three segments whose second-quarter organic growth came from volume as well as price, which makes it the cleanest available mirror for whether anything other than pricing is working[8]. It is also the segment an outside party has proposed to buy outright, so the answer changes what the business is worth to its current owners, and because the segment's cost base is largely fixed plant and distribution capacity, the volume question and the margin question are the same question[23].

The second-quarter data on its own is positive: Building Adhesive Solutions net revenue rose 9.4 percent year-on-year to $245.2 million with organic growth of 6.2 percent that the 10-Q explicitly attributes to an increase in both sales volume and product pricing, while segment adjusted EBITDA rose 10.4 percent to $41.4 million and the margin improved 20 basis points to 16.9 percent[23], and management named glass, infrastructure and mechanical end markets as the source on the call[5]. The alternative reading sits one quarter earlier: Building Adhesive Solutions organic sales fell 5.1 percent year-on-year in the first quarter, which management described as consistent with expectations and executed under challenging weather conditions[7]. Work not done in a cold first quarter does not disappear, it moves; and a segment working through deferred volume looks exactly like a segment winning share for precisely one quarter.

The directness of the financial transmission is what makes the judgment matter: project volume converts into segment net revenue as work is put in place, and because the cost base is largely fixed plant and distribution capacity, incremental volume lands in segment adjusted EBITDA at close to the incremental margin, so a volume reversal removes both the revenue and the margin expansion it produced in the same quarter it occurs. What to watch is whether third-quarter Building Adhesive Solutions organic revenue growth stays positive after the first-half catch-up, whether the 10-Q again attributes organic growth to volume as well as price rather than to price alone, whether the segment adjusted EBITDA margin holds at or above 16.9 percent as mix changes, and whether the company says anything further about the unsolicited proposal for the segment and what that implies about how the board sees the business. The falsifiers are these: organic growth back below zero would identify the second quarter as recovered work; growth attributed to price alone would remove the volume evidence this understanding depends on; and segment adjusted EBITDA below $37.5 million would erase the year-on-year gain entirely.

The company says fiscal 2026 cash delivery is weighted to the second half. Will the fiscal third quarter actually deliver it, so leverage is still falling organically when the Advanced Medical Solutions acquisition debt arrives?

The company has committed to a cash acquisition that it says will take net leverage to 4.0 times on completion from 3.1 times today, and back inside a 2.5 to 3.0 times target within two years of closing[15]. That path is built on cash the company has not generated yet: first-half operating cash flow was $117.2 million against a full-year range of $300 million to $325 million, which leaves roughly $183 million to be produced in the second half to reach the low end[10]. More to the point, a year in which profit comes mainly from price is exactly the kind of year in which profit and cash separate, because price raises the value of receivables and inventory before it raises collections.

The evidence currently runs in both directions. Net debt at the end of the second quarter was $1,958 million and net debt to adjusted EBITDA was 3.1 times, down from 3.4 times a year earlier; second-quarter operating cash flow of $121 million was a record for that quarter, and net working capital improved 260 basis points sequentially to 16.4 percent of annualized net revenue[11]; the July refinancing extended the term A loan and an enlarged $800 million revolver to 2031 and cut interest rate margins by 25 basis points[24]. Against that, first-half operating cash flow was only $117.2 million because the first quarter consumed cash, half-year capital spending was $104.4 million, and receivables and inventory each absorbed more than $50 million[10]. On the transaction itself, AMS shareholders are to receive 285 pence in cash per share, committed bridge facilities are in place, court sanction and regulatory approvals are still required, the long-stop date is June 25, 2027, and the company anticipates completion by the end of calendar 2026[27].

The order of the transmission dictates the order of observation: higher realized prices raise the value of receivables and inventory first and collections later, so net working capital intensity rises before operating cash flow catches up a quarter behind; operating cash flow net of capital spending inflated by Quantum Leap, plus dividends and buybacks, determines net debt; and net debt divided by trailing adjusted EBITDA is the leverage ratio the acquisition financing will be measured against. What to watch is third-quarter operating cash flow against the roughly $183 million the second half needs, whether net working capital stays at or below 16.4 percent of annualized net revenue while pricing keeps rising, the reported net debt to adjusted EBITDA figure and whether the 2.5 to 3.0 times target and its two-year timetable are restated, and whether the acquisition has closed or all conditions are satisfied and guidance is rewritten to include it. The falsifiers: operating cash flow below $90 million in the third quarter would leave the full-year range dependent on the fourth quarter alone; net working capital above 17.0% would show the price increase is being financed rather than collected; and leverage above 3.4x before completion would mean organic deleveraging stopped before the acquisition debt arrived.

Risks and Falsifiers

The first risk is that the petrochemical disruption permanently resets the industry cost base, so today's wider spread is a transition effect rather than a new level. It presses directly on the largest cost line: the purchase of raw materials is the company's largest expenditure, the 10-K puts a one percent change in raw material cost at approximately $12.6 million of fiscal 2025 net income, or $0.23 per diluted share, and management itself says raw material costs are not expected to return to pre-disruption levels[25]. The falsifying observation is specific: raw material cost as a percentage of net revenue deteriorating year-on-year in the third quarter while the price contribution runs at the guided high single-digit rate[21].

The second risk is that portfolio and financing activity crowds out operating execution: a cross-border medical acquisition, an unsolicited proposal for a quarter of the company, and three financing agreements inside two months compete for the same management attention as the Quantum Leap supply chain rebuild. The financial exposure is interest: before any acquisition debt arrives, second-quarter interest expense was already $32.6 million, and the announced financing adds committed bridge facilities on top of the refinanced $420 million term A loan and the $800 million revolver[3][24]; management has also said that extracting non-core assets carries a high risk of dis-synergies because plants are shared across segments[5]. The falsifying signal would be quarterly interest expense rising materially above the $32.6 million run rate before completion, or the company deferring Quantum Leap milestones or restructuring spending in the third-quarter disclosure[26].

The third risk is that price realization decays as petrochemical availability normalizes and competitors return to the market, so the April increase is partly rebated in later negotiations. The arithmetic of the exposure is direct: on roughly $950 million of quarterly net revenue, each percentage point of price is about $9.5 million of revenue, nearly all of which is gross profit because raw material cost is largely contracted within the quarter[3]. The falsifier is a third-quarter price contribution below +6.0% while volume still declines as guided, or adjusted gross margin below 32.2%[8].

The fourth risk is that Engineering Adhesives weakness outlives the solar exit because transportation and general industrial demand stay soft through the second half. The exposure is the quality of profit: the segment produced $63.5 million of segment adjusted EBITDA on $283.2 million of revenue in the second quarter at a 22.4 percent margin, the highest of the three, so a flat-to-declining revenue line withholds the group's most profitable incremental dollar[9]. The falsifier is third-quarter Engineering Adhesives organic revenue growth still negative while management no longer attributes the decline to solar[7].

The fifth risk is that second-quarter strength in Building Adhesive Solutions was deferred first-quarter work rather than durable project demand, so the third quarter gives it back. The exposure is the absolute level of segment profit: the segment produced $41.4 million of segment adjusted EBITDA on $245.2 million of revenue in the second quarter, and returning to the prior-year $37.5 million would remove about $3.9 million of quarterly segment adjusted EBITDA and weaken the board's stated position that the outside proposal undervalues the business[23]. The falsifier is third-quarter Building Adhesive Solutions organic revenue growth below zero, or segment net revenue below $225 million[14].

The sixth risk is that leverage stays above the target band longer than planned because second-half cash conversion falls short while the acquisition debt lands on schedule. The exposure is the whole balance sheet: net debt of $1,958 million at 3.1 times adjusted EBITDA, management's statement that leverage will be 4.0 times on completion excluding synergies, and committed financing that includes bridge facilities alongside the refinanced $420 million term A loan and the $800 million revolver[15]. The falsifier is third-quarter net debt to adjusted EBITDA above 3.4x, or withdrawal of the two-year return to the 2.5 to 3.0 times target[11].

What to Watch Next

• Price and volume together: the second quarter set the baseline at +3.0% pricing, -0.4% volume and a 34.2% adjusted gross margin. Read the two percentages in the third-quarter revenue variance analysis together, and check whether raw material cost as a share of revenue still improves year-on-year. Pricing below +6.0%, volume worse than -7.0%, or adjusted gross margin below 32.2% would each break the current reading.
• Engineering Adhesives after solar: organic revenue was -1.0% with a 22.4% segment margin and solar revenue of about $12.5 million in the first quarter. Watch for positive organic growth reported without an "excluding solar" qualifier, and for whether management still calls out automotive as weak. Organic growth still negative after the disclosed trough, or a segment margin below 21.9%, would falsify it.
• Building Adhesive Solutions volume: organic growth was +6.2% with segment adjusted EBITDA of $41.4 million at a 16.9% margin. Watch whether the 10-Q again attributes growth to volume as well as price. Organic growth back below zero, or segment adjusted EBITDA below $37.5 million, would identify the second quarter as recovered work.
• Cash conversion and deleveraging: first-half operating cash flow was $117.2 million, net working capital 16.4% and leverage 3.1 times. Watch how much of the roughly $183 million the second half needs arrives in this quarter, and whether all acquisition conditions are satisfied. Operating cash flow below $90 million, net working capital above 17.0%, or leverage above 3.4 times would each argue the opposite way.

Conclusion

What produces this company's profit right now is one thing: through the tightness created by the petrochemical disruption, global sourcing preserved its ability to keep supplying customers, that position was converted into a minimum 10 percent global price increase effective April 1, 2026, and the resulting spread fell into gross profit inside the window in which raw material contracts were already fixed[7]. The second-quarter numbers say the mechanism works — 3.0 percentage points of price, a 34.2 percent adjusted gross margin and $181 million of adjusted EBITDA[3] — but they also push the company into an unresolved relationship: the further price rises, the more volume walks away and the more working capital the price ties up, and working capital is precisely where the cash has to come from to service the acquisition debt about to be added. Net debt of $1,958 million at 3.1 times adjusted EBITDA, first-half operating cash flow of $117.2 million and a full-year target of $300 million to $325 million describe a distance, and the third quarter is where that distance starts to be measured[10].

Two independent pieces published after the second quarter each address one end of that chain. Ancora Holdings Group submitted a proposal on August 12, 2026 offering $1.1 billion to $1.2 billion in cash for the entire Building Adhesive Solutions segment, arguing that the transaction would support and accelerate the deleveraging goals management has already stated, let management concentrate on integrating Advanced Medical Solutions while continuing to execute Quantum Leap, and move the company out of a segment it characterizes as lower-margin in a highly fragmented market, and stating that the offer carried no financing contingency; the company's board rejected the proposal[28]. MedTech Dive reported on August 14, 2026 that Advanced Medical Solutions shareholders had approved the 715 million pound sale, quoting H.B. Fuller chief executive Celeste Mastin describing the medical adhesives market as fragmented and highly specialized with meaningful barriers to entry including regulatory approvals, clinical validation and rigorous customer qualification[29]. The two do not conflict on the proposition that the company needs to deleverage faster, but they point to opposite routes: Ancora reads Building Adhesive Solutions as a business to sell for cash, while the second-quarter disclosure shows it growing 6.2 percent organically on volume as well as price with the margin up 20 basis points[23]; the MedTech Dive report, by contrast, removes the largest remaining uncertainty on the acquisition route — the shareholder vote — and turns the question from whether the deal happens into when it happens and whether the cash plan supporting it is on schedule. It should be said that no independently published work in this window disputes the company's own price-cost arithmetic, so these two pieces are the only outside interpretations available, and they are views rather than facts.

The combination that would materially strengthen the current understanding is a third quarter in which the price contribution lands in the high single-digit range management guided to, volume falls no more than mid-single digits, adjusted gross margin holds above 34 percent, Engineering Adhesives reports positive organic growth without an "excluding solar" qualifier, Building Adhesive Solutions organic growth is again attributed to volume as well as price, and operating cash flow delivers most of the roughly $183 million the second half needs while net working capital stays no higher than 16.4 percent of annualized revenue[4]. The combination that would materially weaken it is the mirror image: a price contribution below +6.0%, volume worse than -7.0%, adjusted gross margin below 32.2%, Building Adhesive Solutions organic growth back below zero, operating cash flow under $90 million and net debt to adjusted EBITDA back above 3.4 times — which together would mean that the chain running from price to profit to cash to leverage had broken at its first link before the acquisition debt even arrived[11].

Sources

[1] FUL 10-K FY2025 customers and workforce · 2026-01-22 · 10-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926001767/ful20251130_10k.htm

[2] H.B. Fuller press release 2026-09-09, H.B. Fuller to Report Third Quarter 2026 Results on September 23, 2026 · 2026-09-09 · press release

[3] FUL 8-K filed 2026-06-25 Q2 FY2026 results · 2026-06-25 · 8-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926021622/ex_980922.htm

[4] FUL 8-K filed 2026-06-25 fiscal 2026 outlook · 2026-06-25 · 8-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926021622/ex_980922.htm

[5] FUL Q2 FY2026 earnings call 2026-06-25 · 2026-06-25 · earnings-call · https://investors.hbfuller.com

[6] MarketBeat FUL quarterly earnings preview 2026-09-16 · 2026-09-16 · MarketBeat · https://www.marketbeat.com/instant-alerts/upcoming-h-b-fuller-ful-projected-to-post-quarterly-earnings-on-wednesday-2026-09-16/

[7] FUL Q1 FY2026 earnings call 2026-03-26 · 2026-03-26 · earnings-call · https://investors.hbfuller.com

[8] FUL 10-Q filed 2026-06-25 Q2 FY2026 revenue bridge · 2026-06-25 · 10-Q · https://www.sec.gov/Archives/edgar/data/39368/000143774926021677/ful20260530_10q.htm

[9] FUL 10-Q filed 2026-06-25 EA segment results · 2026-06-25 · 10-Q · https://www.sec.gov/Archives/edgar/data/39368/000143774926021677/ful20260530_10q.htm

[10] FUL 10-Q filed 2026-06-25 first-half cash flow · 2026-06-25 · 10-Q · https://www.sec.gov/Archives/edgar/data/39368/000143774926021677/ful20260530_10q.htm

[11] FUL 8-K filed 2026-06-25 balance sheet and working capital · 2026-06-25 · 8-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926021622/ex_980922.htm

[12] FUL 10-K FY2025 restructuring and international exposure · 2026-01-22 · 10-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926001767/ful20251130_10k.htm

[13] FUL 10-K FY2025 segments and end markets · 2026-01-22 · 10-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926001767/ful20251130_10k.htm

[14] FUL 10-Q filed 2026-06-25 segment structure and adjusted EBITDA · 2026-06-25 · 10-Q · https://www.sec.gov/Archives/edgar/data/39368/000143774926021677/ful20260530_10q.htm

[15] FUL 8-K filed 2026-06-26 AMS leverage and synergies · 2026-06-26 · 8-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926021844/ex_981227.htm

[16] FUL 10-K filed 2026-01-22 · 2026-01-22 · 10-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926001767/ful20251130_10k.htm

[17] FUL 10-K FY2025 revenue variance analysis · 2026-01-22 · 10-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926001767/ful20251130_10k.htm

[18] FUL 10-K FY2025 cost of sales and gross profit · 2026-01-22 · 10-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926001767/ful20251130_10k.htm

[19] FUL 10-Q filed 2026-03-26 Q1 FY2026 revenue bridge · 2026-03-26 · 10-Q · https://www.sec.gov/Archives/edgar/data/39368/000143774926009924/ful20260228_10q.htm

[20] FUL 8-K filed 2026-03-26 Q1 FY2026 results · 2026-03-26 · 8-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926009854/ful20260325_8k.htm

[21] FUL 10-Q filed 2026-06-25 cost of sales · 2026-06-25 · 10-Q · https://www.sec.gov/Archives/edgar/data/39368/000143774926021677/ful20260530_10q.htm

[22] FUL 10-Q filed 2026-06-25 HHC segment results · 2026-06-25 · 10-Q · https://www.sec.gov/Archives/edgar/data/39368/000143774926021677/ful20260530_10q.htm

[23] FUL 10-Q filed 2026-06-25 BAS segment results · 2026-06-25 · 10-Q · https://www.sec.gov/Archives/edgar/data/39368/000143774926021677/ful20260530_10q.htm

[24] FUL 8-K filed 2026-07-20 credit agreement Amendment No. 3 · 2026-07-20 · 8-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926023846/ful20260717_8k.htm

[25] FUL 10-K FY2025 raw material sensitivity · 2026-01-22 · 10-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926001767/ful20251130_10k.htm

[26] FUL 10-Q filed 2026-06-25 restructuring plans · 2026-06-25 · 10-Q · https://www.sec.gov/Archives/edgar/data/39368/000143774926021677/ful20260530_10q.htm

[27] FUL 8-K filed 2026-06-26 AMS Rule 2.7 terms · 2026-06-26 · 8-K · https://www.sec.gov/Archives/edgar/data/39368/000143774926021844/ful20260625_8k.htm

[28] Ancora Holdings Group proposal letter 2026-08-12 · 2026-08-12 · Ancora Holdings Group · https://finance.yahoo.com/markets/stocks/articles/ancora-holdings-group-submits-proposal-133000588.html

[29] MedTech Dive AMS shareholder approval 2026-08-14 · 2026-08-14 · MedTech Dive · https://www.medtechdive.com/news/ams-secures-shareholder-support-for-planned-sale-to-hb-fuller/827884/